Assessment of Host-targeted Nanobody Therapeutics
DEPT OF DEFENSE
About this archived opportunity
Numerous neurotropic viral families are considered high priority pathogens to the Department of War (DOW), but the therapeutic decelopment in stymied by the difficulty of trafficking into into the Central Nervous System (CNS). This is mediated primarily by blood-brain barrier (BBB) tight junctions that prevent large molecules entry into the parenchymal space. However, the CNS has significant physiologically needs in the form of energy, oxygen and other molecular components. See Statement of Objectives (SOO) for specific information.
Historical details
- Status
- Closed
- Deadline
- January 21, 2026
- First captured
- January 11, 2026
- Publisher reference
- 37a309976cd744b89e169bddc7ba06fb
Eligibility: No Set aside used. NONE
This opportunity has closed
Assessment of Host-targeted Nanobody Therapeutics
by DEPT OF DEFENSE
Get notified when similar opportunities open
We'll save this search and email you when new assessment, host, targeted opportunities are posted. Free.